| Anaplastic Large Cell Lymphoma, ALK-Positive studied in …STUDIED_INderived10 of 20show all (up to 200) |
|---|
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729397Phase 1 · not yet recruiting Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176690Phase 1 · recruiting Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03505554Phase 2 · completed A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07013565Phase 2 · recruiting Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925609Phase 1/Phase 2 · recruiting Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03493451Phase 2 · completed Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01979536Phase 2 · completed Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |